Logo image of SEPN

SEPTERNA INC (SEPN) Stock Fundamental Analysis

NASDAQ:SEPN - Nasdaq - US81734D1046 - Currency: USD

5.76  -0.13 (-2.21%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SEPN. SEPN was compared to 194 industry peers in the Pharmaceuticals industry. SEPN has a great financial health rating, but its profitability evaluates not so good. SEPN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SEPN was profitable.
SEPN Yearly Net Income VS EBIT VS OCF VS FCFSEPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 0 -10M -20M -30M -40M

1.2 Ratios

SEPN's Return On Assets of 0.33% is amongst the best of the industry. SEPN outperforms 82.16% of its industry peers.
With an excellent Return On Equity value of 0.41%, SEPN belongs to the best of the industry, outperforming 82.70% of the companies in the same industry.
Industry RankSector Rank
ROA 0.33%
ROE 0.41%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEPN Yearly ROA, ROE, ROICSEPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 0 -20 -40 -60 -80

1.3 Margins

Looking at the Profit Margin, with a value of 375.50%, SEPN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for SEPN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 375.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEPN Yearly Profit, Operating, Gross MarginsSEPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SEPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SEPN has about the same amout of shares outstanding than it did 1 year ago.
SEPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SEPN Yearly Shares OutstandingSEPN Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 10M 20M 30M 40M
SEPN Yearly Total Debt VS Total AssetsSEPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SEPN has an Altman-Z score of 3.36. This indicates that SEPN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.36, SEPN is doing good in the industry, outperforming 75.68% of the companies in the same industry.
There is no outstanding debt for SEPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.36
ROIC/WACCN/A
WACC9.88%
SEPN Yearly LT Debt VS Equity VS FCFSEPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M 100M

2.3 Liquidity

SEPN has a Current Ratio of 10.08. This indicates that SEPN is financially healthy and has no problem in meeting its short term obligations.
SEPN has a Current ratio of 10.08. This is amongst the best in the industry. SEPN outperforms 82.16% of its industry peers.
A Quick Ratio of 10.08 indicates that SEPN has no problem at all paying its short term obligations.
SEPN has a Quick ratio of 10.08. This is amongst the best in the industry. SEPN outperforms 82.16% of its industry peers.
Industry RankSector Rank
Current Ratio 10.08
Quick Ratio 10.08
SEPN Yearly Current Assets VS Current LiabilitesSEPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 102.05% over the past year.
EPS 1Y (TTM)102.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SEPN will show a very negative growth in Earnings Per Share. The EPS will decrease by -509.99% on average per year.
Based on estimates for the next years, SEPN will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-58693.33%
EPS Next 2Y-1296.58%
EPS Next 3Y-509.99%
EPS Next 5YN/A
Revenue Next Year406.62%
Revenue Next 2Y53.76%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

SEPN Yearly Revenue VS EstimatesSEPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 200K 400K 600K
SEPN Yearly EPS VS EstimatesSEPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 576.00, SEPN can be considered very expensive at the moment.
78.92% of the companies in the same industry are more expensive than SEPN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 30.30, SEPN is valued quite expensively.
SEPN is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 576
Fwd PE N/A
SEPN Price Earnings VS Forward Price EarningsSEPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300 400 500

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEPN Per share dataSEPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

SEPN's earnings are expected to decrease with -509.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1296.58%
EPS Next 3Y-509.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SEPN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEPTERNA INC

NASDAQ:SEPN (2/21/2025, 12:35:11 PM)

5.76

-0.13 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change80.05%
Market Cap255.74M
Analysts82
Price Target44.54 (673.26%)
Short Float %5.41%
Short Ratio6.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 576
Fwd PE N/A
P/S 1693.67
P/FCF N/A
P/OCF N/A
P/B 1.87
P/tB 1.87
EV/EBITDA N/A
EPS(TTM)0.01
EY0.17%
EPS(NY)-2.61
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.33%
ROE 0.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 375.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.08
Quick Ratio 10.08
Altman-Z 3.36
F-ScoreN/A
WACC9.88%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-58693.33%
EPS Next 2Y-1296.58%
EPS Next 3Y-509.99%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year406.62%
Revenue Next 2Y53.76%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-62.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-85.86%
EBIT Next 3Y-54.91%
EBIT Next 5YN/A
FCF growth 1Y-69.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.17%
OCF growth 3YN/A
OCF growth 5YN/A